NO965087L - Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav - Google Patents

Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav

Info

Publication number
NO965087L
NO965087L NO965087A NO965087A NO965087L NO 965087 L NO965087 L NO 965087L NO 965087 A NO965087 A NO 965087A NO 965087 A NO965087 A NO 965087A NO 965087 L NO965087 L NO 965087L
Authority
NO
Norway
Prior art keywords
hla
antigen precursor
nucleic acid
acid molecule
tumor rejection
Prior art date
Application number
NO965087A
Other languages
English (en)
Other versions
NO965087D0 (no
Inventor
Thierry Boon-Falleur
Pierre Coulie
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/253,503 external-priority patent/US5589334A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO965087D0 publication Critical patent/NO965087D0/no
Publication of NO965087L publication Critical patent/NO965087L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

Det beskrives et nukleinsyremolekyl som koder for en tumorantigenforløper som deretter bearbeides til antigener som presenteres av et HLA-molekyl. HLA-molekylet kan være HLA-A2, HLA-A28, HLA-B13, HLA-B44 eller HLA-Cw6. Anti- genene beskriver også. Disse materialer er anvendelige i diagnostiske og terapeutiske fremgangsmåter. Tumorrejek- sjonsantigenforløperen er ikke tyrosinase, som tidligere har blitt identifisert som en tumorrejeksjonsantigenfor- løper bearbeidet til et antigen som blir presentert av HLA-B44. Figurene viser data for cytolytisk aktivitet av lymfocytter oppnådd i autologe blandete lymfocytt-tumor- celle-kulturer.
NO965087A 1994-06-03 1996-11-29 Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav NO965087L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/253,503 US5589334A (en) 1994-06-03 1994-06-03 Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof
US08/373,636 US5997870A (en) 1994-06-03 1995-01-17 Isolated peptides which bind to HLA-B44 Molecules
PCT/US1995/006852 WO1995033855A1 (en) 1994-06-03 1995-05-31 Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor, and uses thereof

Publications (2)

Publication Number Publication Date
NO965087D0 NO965087D0 (no) 1996-11-29
NO965087L true NO965087L (no) 1996-12-03

Family

ID=26943319

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965087A NO965087L (no) 1994-06-03 1996-11-29 Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav

Country Status (10)

Country Link
US (2) US5997870A (no)
EP (1) EP0771358A4 (no)
JP (1) JPH10501409A (no)
CN (1) CN1149889A (no)
AU (1) AU687572B2 (no)
CA (1) CA2191728A1 (no)
FI (1) FI964812A0 (no)
NO (1) NO965087L (no)
NZ (1) NZ288414A (no)
WO (1) WO1995033855A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
WO1998026091A2 (en) * 1996-12-12 1998-06-18 Visible Genetics, Inc. Method and kit for hla class i typing
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
WO1996010413A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor

Also Published As

Publication number Publication date
NZ288414A (en) 1997-10-24
EP0771358A4 (en) 1999-05-19
EP0771358A1 (en) 1997-05-07
NO965087D0 (no) 1996-11-29
JPH10501409A (ja) 1998-02-10
US5997870A (en) 1999-12-07
CA2191728A1 (en) 1995-12-14
AU2763595A (en) 1996-01-04
US6245333B1 (en) 2001-06-12
FI964812A (fi) 1996-12-02
CN1149889A (zh) 1997-05-14
WO1995033855A1 (en) 1995-12-14
FI964812A0 (fi) 1996-12-02
AU687572B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
ES2161875T3 (es) Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.
Gery et al. Potentiation of the T-lymphocyte response to mitogens: II. the cellular source of potentiating mediator (s)
Pross et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells: VI. A brief review
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
DK0759032T3 (da) Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
BAGNASCO et al. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity
Mazzocchi et al. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T‐cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor‐invaded lymph nodes of melanoma patients
Dennert et al. Continuously proliferating allospecific T cells, lifespan and antigen receptors
WAGNER et al. Subcellular mouse alloantigens: Cytotoxic immune responses and specific blocking in vitro
Jerry et al. Fetal antigens in nonneoplastic conditions
DE3585049D1 (de) Monoklonale antikoerper.
Kievits et al. A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules.
US4017361A (en) Process for obtaining continuous lines of tumoral cells in vitro
Evans et al. Amplification of immune T lymphocyte function in situ: the identification of active components of the immunologic network during tumor rejection.
Schechter et al. Generation of suppressor lymphocytes during sensitization in culture against a syngeneic tumor: affinity chromatography on insolubilized histamine
FI881122A (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
Scheynius et al. Epidermal Langerhans cells as accessory cells in Con A stimulation of T lymphocytes in the guinea‐pig
FURUHATA et al. Frequencies of Rh and Kidd blood types and private and public antigens among the Japanese
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
AU6659390A (en) Methods for utilizing cell lines which lack human class ii histocompatibility antigens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application